Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc1303641 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapy with clopidogrel or rivaroxaban has equivalent impacts on recurrence of thromboembolism and survival in cats following cardiogenic thromboembolism: the SUPERCAT study.
J Am Vet Med Assoc
December 2024
6Department of Clinical Sciences and Advanced Medicine, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.
Objective: To assess the impact of clopidogrel or rivaroxaban administration on recurrence of arterial thromboembolism (ATE) in cats that have recovered from cardiogenic ATE.
Methods: This multicenter prospective double-masked protocol enrolled 45 cats that had recovered from cardiogenic ATE and were randomized to receive either clopidogrel (18.75 mg/cat, PO; n = 19) or rivaroxaban (2.
Is Aspirin Safe for Thromboprophylaxis After Surgery for Lower Extremity Neoplastic Pathologic Fractures?
J Surg Oncol
November 2024
Department of Orthopaedic Surgery, University of California, Los Angeles, Los Angeles, California, USA.
Article Synopsis
- This study investigates the rates of venous thromboembolism (VTE) among patients undergoing surgery for cancer-related bone fractures while receiving different anticoagulants: enoxaparin, apixaban, rivaroxaban, or aspirin (ASA).
- Analysis was conducted using patient data from the Premier Healthcare Database between 2015 and 2021, comparing VTE occurrences among the different medication cohorts, with enoxaparin as the control.
- Results indicated that enoxaparin was associated with lower VTE rates compared to apixaban but higher than those treated with ASA, suggesting that ASA may be a safer option for certain patients with minimal risk factors for VTE post-surgery.
Rivaroxaban for Thromboembolism Prophylaxis in Patients with Nephrotic Syndrome: A Single-Arm, Prospective Study.
Kidney Dis (Basel)
October 2024
Key Laboratory of Drug Quality Control and Pharmacovigilance, Ministry of Education, School of Pharmacy, China Pharmaceutical University, Nanjing, China.
Introduction: Thromboembolism is a recognized complication of nephrotic syndrome (NS). Evidence supporting the use of rivaroxaban to prevent NS-related thrombosis is limited and controversial. This study aimed to explore the impact of NS on rivaroxaban pharmacokinetics and to collect observational data on the efficacy and safety of rivaroxaban as primary thromboprophylaxis in patients with NS.
View Article and Find Full Text PDFComparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban in dogs.
J Vet Intern Med
November 2024
Comparative Coagulation Laboratory, Department of Population Medicine and Diagnostic Sciences, Cornell University College of Veterinary Medicine, Ithaca, New York, USA.
Background: Comparative pharmacokinetics and pharmacodynamics (PK/PD) of apixaban and rivaroxaban have not been studied in dogs and the propensity of these drugs to cause hypercoagulability after discontinuation is unknown.
Hypothesis: Compare the PK/PD of clinical dosing regimens of PO apixaban and rivaroxaban administered repeatedly to healthy dogs and assess the effect of abrupt drug discontinuation on coagulation.
Animals: Six University-owned, purpose-bred, middle-aged, mixed-breed dogs (4 male, 2 female).
Methods of a cluster-randomized, type II hybrid implementation effectiveness trial to prospectively assess extended-duration thromboprophylaxis for at-risk medical patients being discharged to prevent hospital-associated venous thromboembolism.
Res Pract Thromb Haemost
August 2024
Intermountain Medical Center Department of Medicine, Intermountain Health, Salt Lake City, Utah, USA.
Article Synopsis
- Venous thromboembolism (VTE) is a significant cause of preventable hospital deaths, especially in medically ill patients, with the risk of symptomatic VTE doubling after discharge.
- The eVTE trial aims to implement a system that alerts at-risk patients about postdischarge thromboprophylaxis, specifically using rivaroxaban, in a 23-hospital healthcare network.
- This study will assess the prescription rates, alongside efficacy and safety outcomes related to VTE, heart attacks, strokes, and major bleeding, using a framework for effective implementation and reporting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!